Bernard Coulie - 23 Jan 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
President and CEO, Director
Signature
/s/ Mike Ouimette, attorney-in-fact
Issuer symbol
PLRX
Transactions as of
23 Jan 2023
Net transactions value
-$1,893,873
Form type
4
Filing time
25 Jan 2023, 20:00:55 UTC
Previous filing
09 Jan 2023
Next filing
27 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Options Exercise $31,200 +15,000 +16% $2.08* 108,812 23 Jan 2023 Direct
transaction PLRX Common Stock Sale $342,163 -10,150 -9.3% $33.71 98,662 23 Jan 2023 Direct F1, F2
transaction PLRX Common Stock Sale $169,405 -4,850 -4.9% $34.93 93,812 23 Jan 2023 Direct F1, F3
transaction PLRX Common Stock Sale $525,000 -15,000 -3.3% $35.00 434,317 23 Jan 2023 See footnote F4, F5
transaction PLRX Common Stock Options Exercise $31,200 +15,000 +16% $2.08* 108,812 24 Jan 2023 Direct
transaction PLRX Common Stock Sale $463,389 -15,000 -14% $30.89 93,812 24 Jan 2023 Direct F1, F6
transaction PLRX Common Stock Options Exercise $31,200 +15,000 +16% $2.08* 108,812 25 Jan 2023 Direct
transaction PLRX Common Stock Sale $431,058 -13,304 -12% $32.40 95,508 25 Jan 2023 Direct F1, F7
transaction PLRX Common Stock Sale $56,459 -1,696 -1.8% $33.29 93,812 25 Jan 2023 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLRX Stock Option (right to buy) Options Exercise $0 -15,000 -6.1% $0.000000 232,380 23 Jan 2023 Common Stock 15,000 $2.08 Direct F9
transaction PLRX Stock Option (right to buy) Options Exercise $0 -15,000 -6.5% $0.000000 217,380 24 Jan 2023 Common Stock 15,000 $2.08 Direct F9
transaction PLRX Stock Option (right to buy) Options Exercise $0 -15,000 -6.9% $0.000000 202,380 25 Jan 2023 Common Stock 15,000 $2.08 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.40 to $34.34, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.43 to $35.00, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
F4 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.
F5 Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.42 to $31.38, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.
F7 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.95 to $32.90, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4.
F8 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.66, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) to this Form 4.
F9 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.